<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577132</url>
  </required_header>
  <id_info>
    <org_study_id>SeoulNUHUro_Atezolizumab</org_study_id>
    <nct_id>NCT03577132</nct_id>
  </id_info>
  <brief_title>The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer</brief_title>
  <official_title>The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer According to the BASQ Classification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, promising evidences that blocking PD-1 and PD-L1 is an efficacious way to treat
      advanced stage bladder cancer patients. Atezolimumab is the first PD-L1 inhibitor approved by
      US FDA for advanced UBC in June 2014. These novel agents will become the standard therapy for
      unhopeful UBC patients who fail to respond to cisplatin-based chemotherapy and finally, the
      first-line treatment would be changed from cisplatin-based chemotherapy to immune check point
      inhibitors for advanced UBC, particularly neoadjuvant setting.

      Additionally, along with enormous analysis of genomic landscape of bladder cancer, a
      consensus was reached regarding the existence of a group of Basal-Squamous-like tumors -
      designated BASQ - characterized the high expression of KRT5/6 and KRT14 and low/undetectable
      expression of FOXA1 and GATA3. This novel molecular classification can improve the
      identification of optimal patient population for different treatment modalities.
      Specifically, luminal type and basal type may have different treatment response and prognosis
      after initial definitive treatment, such as neoadjuvant treatments.

      However, there is no evidence for this topic, particularly the clinical efficacy of
      neoadjuvant PD-L1 inhibitors according to the BASQ classification in patients with advanced
      urothelial bladder cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective pathological responses (pT0 change)</measure>
    <time_frame>4weeks</time_frame>
    <description>Final pathology of bladder after operation (radical cystectomy)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival at 1yr</measure>
    <time_frame>1year</time_frame>
    <description>progression-free survival at 1yr</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Luminal type</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Luminal type in previous transurethral resection of bladder tumor pathology. Luminal type in Immunohistochemistry (KRT5/6-KRT14-FOXA1+GATA3+)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basal typr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basal type in previous transurethral resection of bladder tumor pathology. Basal type in Immunohistochemistry (KRT5/6+KRT14+FOXA1-GATA3-)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant atezolizumab</intervention_name>
    <description>Atezolimumab
At a fixed dose of 1200 mg as a 60-minute intravenous infusion (1st), then as a 30-minute intravenous infusion (2nd and 3rd)
Every 3 weeks, for a total of 3 cycles prior to radical cystectomy</description>
    <arm_group_label>Basal typr</arm_group_label>
    <arm_group_label>Luminal type</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years of age

          -  Histologically confirmed muscle-invasive urothelial carcinoma

          -  Patients undergoing radical cystectomy

          -  Advanced status requiring neoadjuvant systemic therapy

          -  ECOG performance status score of 0 or 1

          -  Adequate organ and hematologic functions

          -  Available IHC data for the BASQ classification

        Exclusion Criteria:

          -  Non-urothelial carcinoma histology

          -  Active autoimmune disease or inflammatory bowel disease

          -  Prior severe or persistent immune-related adverse events

          -  Previous exposure to anti-PD-1 or anti-PD-L1 therapy

          -  Requirement for 10 mg/d of prednisone or equivalent

          -  Inadequate liver, kidney function and hematologic dysfunction

          -  Inoperable case, such as untreated CNS metastases

          -  No available archival tumor tissue for evaluating the BASQ classification
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ja Hyeon Ku, M.D.,PH.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ja Hyeon Ku, M.D.,PH.D</last_name>
    <phone>+82-2-2072-0361</phone>
    <email>randyku@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyeongdong Yuk, M.D.</last_name>
    <phone>+82-2-2072-1968</phone>
    <email>hinayuk@naver.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28;349(9):859-66. Erratum in: N Engl J Med. 2003 Nov 6;349(19):1880.</citation>
    <PMID>12944571</PMID>
  </reference>
  <reference>
    <citation>von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005 Jul 20;23(21):4602-8.</citation>
    <PMID>16034041</PMID>
  </reference>
  <reference>
    <citation>Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014 Mar 20;507(7492):315-22. doi: 10.1038/nature12965. Epub 2014 Jan 29.</citation>
    <PMID>24476821</PMID>
  </reference>
  <reference>
    <citation>Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014 Jul;11(7):400-10. doi: 10.1038/nrurol.2014.129. Epub 2014 Jun 24. Review.</citation>
    <PMID>24960601</PMID>
  </reference>
  <reference>
    <citation>Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Erratum in: Lancet. 2017 Aug 26;390(10097):848.</citation>
    <PMID>27939400</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Ja Hyeon Ku</investigator_full_name>
    <investigator_title>Professor, MD., PHD.</investigator_title>
  </responsible_party>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>atezolizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

